Aclaris Therapeutics (ACRS) Other Gross PP&E Adjustments: 2017-2025
Historic Other Gross PP&E Adjustments for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $5.8 million.
- Aclaris Therapeutics' Other Gross PP&E Adjustments fell 0.31% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 18.80%. This contributed to the annual value of -$13.3 million for FY2024, which is 8.27% down from last year.
- Per Aclaris Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at $5.8 million for Q3 2025, which was down 1.41% from $5.9 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Other Gross PP&E Adjustments ranged from a high of $6.3 million in Q3 2023 and a low of -$14.3 million during Q4 2022.
- For the 3-year period, Aclaris Therapeutics' Other Gross PP&E Adjustments averaged around $2.5 million, with its median value being $5.8 million (2024).
- Per our database at Business Quant, Aclaris Therapeutics' Other Gross PP&E Adjustments fell by 26.84% in 2021 and then climbed by 27.18% in 2023.
- Aclaris Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at -$13.0 million in 2021, then fell by 9.98% to -$14.3 million in 2022, then increased by 14.16% to -$12.3 million in 2023, then fell by 8.27% to -$13.3 million in 2024, then dropped by 0.31% to $5.8 million in 2025.
- Its Other Gross PP&E Adjustments was $5.8 million in Q3 2025, compared to $5.9 million in Q2 2025 and $5.9 million in Q1 2025.